SCHEMBL5137101

SCHEMBL5137101

CCCCN(Cc1cccc(O)c1)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 5/20 0.42
BCL2L2 Q92843 1/20 0.42
DRD2 P14416 3/20 0.41
OPRM1 P35372 3/20 0.41
DRD3 P35462 3/20 0.41
OPRD1 P41143 3/20 0.41
OPRK1 P41145 3/20 0.41
C5AR1 P21730 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTR7 P34969 1/20 0.37
CASR P41180 1/20 0.37
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
CRHR1 P34998 2/20 0.35
HSD17B1 P14061 2/20 0.35
HSD17B2 P37059 2/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138077 0.91 C5AR1 (0.39) BCHEBCL2L2C5AR1TAAR1MEN1
SCHEMBL5136086 0.90 C5AR1 (0.41) BCL2L2DRD2DRD3C5AR1TAAR1
SCHEMBL5134684 0.90 C5AR1 (0.41) BCHEBCL2L2DRD2DRD3C5AR1
SCHEMBL5136839 0.89 C5AR1 (0.42) BCL2L2DRD2DRD3C5AR1TAAR1
SCHEMBL5135984 0.89 BCL2L2 (0.39) BCHEBCL2L2DRD2DRD3C5AR1
SCHEMBL5136826 0.89 OPRM1 (0.47) BCHEDRD2OPRM1DRD3OPRD1
SCHEMBL5135618 0.87 DRD2 (0.41) BCHEDRD2OPRM1DRD3OPRD1
SCHEMBL5134767 0.87 MAPT (0.40) BCL2L2DRD2DRD3C5AR1TAAR1
SCHEMBL5136254 0.86 C5AR1 (0.39) BCHEBCL2L2DRD2DRD3C5AR1
SCHEMBL5135930 0.86 C5AR1 (0.36) BCHEBCL2L2C5AR1TAAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed